BI 764532
Boehringer Ingelheim
['lung', 'dll3', 'sclc']
#bispecific #antibodies targeting dll3 and cd3. by engaging and/or harnessing the immune system's power, these innovative therapies may offer new hope/treatments in the fight against small cell lung cancer. #bispecifics #sclc #cancerresearch #asco23 #lungcancer #immunotherapy 
What’s happening in the treatment world of Cancer and Medicine